Browsing by Author "Afolabi, Muibat"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Jadelle sub-dermal implant: evaluation of acceptance, effectiveness, side effects and discontinuation in Ilorin, Nigeria(School of Medicine, Kenyatta University, Kenya, 2014) Balogun, Olayinka; Afolabi, Muibat; Adeniran, Abiodun; Saidu, RakiyaObjective: To determine the safety, efficacy, acceptability, side effects and discontinuation pattern of Jadelle® subdermal implant.Design: A retrospective descriptive study. Setting: The Family Planning Clinic of the University of Ilorin Teaching Hospital [UITH], Ilorin, Kwara State, Nigeria. Subjects: All clients who accepted Jadelle® sub-dermal implant between 1st January 2008 and 31st December 2012. Data was collected from the individual patient case files and analysed using SPSS version 20. Main outcome measures: The prevalence, efficacy, side effects and discontinuation among users of Jadelle®. Results: Of the 2,324 clients during the study period, 108 chose Jadelle® with prevalence of 4.7%. Among these acceptors, 23 (21.3%) had side-effects following insertion. The commonest side effect was menstrual irregularities (60.9%). Twelve acceptors (11.1%) discontinued before the due date for the removal of the insert. Insertion after oneyear from last childbirth (p 0.021) andtwo or more side effects (p 0.001) were significant predictors of discontinuation while previous contraceptive use, number of children alive and age were statistically insignificant. The pearl index was 0 during the study period. Conclusion: Jadelle® is an acceptable contraceptive and the side effects are tolerable to most clients in the study.Item Pregnancy outcomes in booked HIV positive women initiating highly active antiretroviral therapy(School of Medicine and Health Sciences, University forDevelopment Studies, Tamale, Ghana, 2014) Adeniran, Abiodun; Afolabi, Muibat; Saidu, RakiyatPregnancy outcomes in HIV positive women remain a concern especially in sub-Saharan Africa which bears the highest burden of the disease. To evaluate pregnancy outcomes in booked preg-nant women on Highly Active Antiretroviral Therapy (HAART) at the University of Ilorin Teach-ing Hospital (UITH), Ilorin, Nigeria; a case control study (with women initiating HAART in preg-nancy as subjects and those who initiated it before pregnancy as control) of 268 HIV-positive wom-en managed between March 2009 and February 2013 was undertaken at the hospital. Inclusion cri-teria comprised HIV-positivity, booking, antenatal care and delivery at the study site. From the total of 8,958 women who had antenatal care during the period, 502 had HIV infection (prevalence 5.6%) out of which 268 satisfied the inclusion criteria and were enrolled into the study. Subjects were 54(20.2%) while 214(79.8%) were controls; the mean age of participants was 31.0±4.5 years while mean parity was 2.0±1.5. Pregnancy outcomes were worse in subjects with statistical signifi-cance in miscarriage (11.1% vs. 0.9%; OR 11.78, 95% CI 2.07-87.03, p <0.01), preterm delivery (31.5% vs. 1.9%; OR 24.35, 95% CI 7.15-91.26, p<0.01), term pregnancy (42.6% vs. 96.3%; OR 0.03, 95% CI 0.01-0.08, p<0.01), birth asphyxia (OR 8.31, 95% CI 3.25-21.45 p<0.01), low birth weight babies (OR 260.0, 95% CI 66.51-1142.77, p<0.01) and maternal puerperal complications (anaemia 35.2% vs. 0.9%; OR 68.79, 95% CI 14.28-452.19, p <0.01). Mother to child transmission of HIV was recorded in only 3(1.1%) babies among the subjects. Commencement of HAART before pregnancy appears to improve pregnancy outcomes in HIV positive women.